Comparison of the effects of monotherapy with exenatide or metformin to combined exenatide and metformin therapy on menstrual cyclicity in overweight women with polycystic ovary syndrome
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Exenatide (Primary) ; Metformin
- Indications Obesity; Polycystic ovary syndrome; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 07 Sep 2008 Results presented at the 44th Annual Meeting of the European Association for the Study of Diabetes.
- 11 Jul 2007 Status change from in progress to completed.
- 04 Nov 2006 New trial record.